FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use
Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:ATP2A2-IFT81

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: ATP2A2-IFT81
FusionPDB ID: 7837
FusionGDB2.0 ID: 7837
HgeneTgene
Gene symbol

ATP2A2

IFT81

Gene ID

488

28981

Gene nameATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2intraflagellar transport 81
SynonymsATP2B|DAR|DD|SERCA2CDV-1|CDV-1R|CDV1|CDV1R|DV1|SRTD19
Cytomap

12q24.11

12q24.11

Type of geneprotein-codingprotein-coding
Descriptionsarcoplasmic/endoplasmic reticulum calcium ATPase 2ATPase Ca++ transporting cardiac muscle slow twitch 2ATPase, Ca++ dependent, slow-twitch, cardiac muscle-2SR Ca(2+)-ATPase 2calcium pump 2calcium-transporting ATPase sarcoplasmic reticulum type, slowintraflagellar transport protein 81 homologcarnitine deficiency-associated gene expressed in ventricle 1carnitine deficiency-associated protein expressed in ventricle 1
Modification date2020031320200313
UniProtAcc

P16615

Main function of 5'-partner protein: FUNCTION: This magnesium-dependent enzyme catalyzes the hydrolysis of ATP coupled with the translocation of calcium from the cytosol to the sarcoplasmic reticulum lumen (PubMed:16402920). Involved in autophagy in response to starvation. Upon interaction with VMP1 and activation, controls ER-isolation membrane contacts for autophagosome formation (PubMed:28890335). Also modulates ER contacts with lipid droplets, mitochondria and endosomes (PubMed:28890335). {ECO:0000269|PubMed:16402920, ECO:0000269|PubMed:28890335}.; FUNCTION: [Isoform 2]: Involved in the regulation of the contraction/relaxation cycle. Acts as a regulator of TNFSF11-mediated Ca(2+) signaling pathways via its interaction with TMEM64 which is critical for the TNFSF11-induced CREB1 activation and mitochondrial ROS generation necessary for proper osteoclast generation. Association between TMEM64 and SERCA2 in the ER leads to cytosolic Ca(2+) spiking for activation of NFATC1 and production of mitochondrial ROS, thereby triggering Ca(2+) signaling cascades that promote osteoclast differentiation and activation. {ECO:0000250|UniProtKB:O55143}.

Q8WYA0

Main function of 5'-partner protein: FUNCTION: Component of the intraflagellar transport (IFT) complex B: together with IFT74, forms a tubulin-binding module that specifically mediates transport of tubulin within the cilium. Binds tubulin via its CH (calponin-homology)-like region (PubMed:23990561). Required for ciliogenesis (PubMed:27666822, PubMed:23990561). Required for proper regulation of SHH signaling (PubMed:27666822). {ECO:0000269|PubMed:23990561, ECO:0000269|PubMed:27666822}.
Ensembl transtripts involved in fusion geneENST idsENST00000550248, ENST00000308664, 
ENST00000395494, ENST00000539276, 
ENST00000552636, 		ENST00000242591, 
ENST00000361948, ENST00000552912, 
ENST00000549009, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score17 X 22 X 11=41146 X 8 X 8=384
# samples 2712
** MAII scorelog2(27/4114*10)=-3.9295104814741
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0		log2(12/384*10)=-1.67807190511264
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: ATP2A2 [Title/Abstract] AND IFT81 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: ATP2A2 [Title/Abstract] AND IFT81 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)ATP2A2(110720600)-IFT81(110628725), # samples:2
Anticipated loss of major functional domain due to fusion event.ATP2A2-IFT81 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
ATP2A2-IFT81 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
ATP2A2-IFT81 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
ATP2A2-IFT81 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
ATP2A2-IFT81 seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneATP2A2

GO:0032469

endoplasmic reticulum calcium ion homeostasis

16402920

HgeneATP2A2

GO:0032470

positive regulation of endoplasmic reticulum calcium ion concentration

16402920

HgeneATP2A2

GO:0070588

calcium ion transmembrane transport

16402920

HgeneATP2A2

GO:1903515

calcium ion transport from cytosol to endoplasmic reticulum

16402920



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr12:110720600/chr12:110628725)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across ATP2A2 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across IFT81 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)		BP loci
(transcript)		Predicted start
(transcript)		Predicted stop
(transcript)		Seq length
(amino acids)
ENST00000308664ATP2A2chr12110765822-ENST00000552912IFT81chr12110600724+330817693292758809
ENST00000308664ATP2A2chr12110765822-ENST00000242591IFT81chr12110600724+333017693292758809
ENST00000308664ATP2A2chr12110765822-ENST00000361948IFT81chr12110600724+322817693292023564
ENST00000395494ATP2A2chr12110765822-ENST00000552912IFT81chr12110600724+311615772182566782
ENST00000395494ATP2A2chr12110765822-ENST00000242591IFT81chr12110600724+313815772182566782
ENST00000395494ATP2A2chr12110765822-ENST00000361948IFT81chr12110600724+303615772181831537
ENST00000539276ATP2A2chr12110765822-ENST00000552912IFT81chr12110600724+274312041092193694
ENST00000539276ATP2A2chr12110765822-ENST00000242591IFT81chr12110600724+276512041092193694
ENST00000539276ATP2A2chr12110765822-ENST00000361948IFT81chr12110600724+266312041091458449

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000308664ENST00000552912ATP2A2chr12110765822-IFT81chr12110600724+0.0031752840.99682474
ENST00000308664ENST00000242591ATP2A2chr12110765822-IFT81chr12110600724+0.0030995950.99690044
ENST00000308664ENST00000361948ATP2A2chr12110765822-IFT81chr12110600724+0.0027232450.9972767
ENST00000395494ENST00000552912ATP2A2chr12110765822-IFT81chr12110600724+0.0023732190.99762684
ENST00000395494ENST00000242591ATP2A2chr12110765822-IFT81chr12110600724+0.0022920920.99770784
ENST00000395494ENST00000361948ATP2A2chr12110765822-IFT81chr12110600724+0.0017928610.9982071
ENST00000539276ENST00000552912ATP2A2chr12110765822-IFT81chr12110600724+0.0032573040.99674267
ENST00000539276ENST00000242591ATP2A2chr12110765822-IFT81chr12110600724+0.0031722550.9968278
ENST00000539276ENST00000361948ATP2A2chr12110765822-IFT81chr12110600724+0.0020162460.9979837

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for ATP2A2-IFT81

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
ATP2A2chr12110765822IFT81chr121106007241204365TGTLTTNQMSVCRASIISRKKEAKAE
ATP2A2chr12110765822IFT81chr121106007241577453TGTLTTNQMSVCRASIISRKKEAKAE
ATP2A2chr12110765822IFT81chr121106007241769480TGTLTTNQMSVCRASIISRKKEAKAE

Top

Potential FusionNeoAntigen Information of ATP2A2-IFT81 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
ATP2A2-IFT81_110765822_110600724.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
ATP2A2-IFT81chr12110765822chr121106007241769HLA-B27:05CRASIISRK0.9970.83771120
ATP2A2-IFT81chr12110765822chr121106007241769HLA-A30:08RASIISRKK0.99470.75111221
ATP2A2-IFT81chr12110765822chr121106007241769HLA-B27:14CRASIISRK0.97930.70351120
ATP2A2-IFT81chr12110765822chr121106007241769HLA-B27:03CRASIISRK0.92780.85711120
ATP2A2-IFT81chr12110765822chr121106007241769HLA-B27:14VCRASIISRK0.72630.73841020
ATP2A2-IFT81chr12110765822chr121106007241769HLA-B27:14SVCRASIISRK0.66830.7941920
ATP2A2-IFT81chr12110765822chr121106007241769HLA-B27:10CRASIISRK0.99670.78191120
ATP2A2-IFT81chr12110765822chr121106007241769HLA-A30:01RASIISRKK0.9950.83521221
ATP2A2-IFT81chr12110765822chr121106007241769HLA-B27:10SVCRASIISRK0.72090.8588920

Top

Potential FusionNeoAntigen Information of ATP2A2-IFT81 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
ATP2A2-IFT81_110765822_110600724.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1102CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1102VCRASIISRKKEAKA1025
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1103CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1103VCRASIISRKKEAKA1025
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1114CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1116CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1116VCRASIISRKKEAKA1025
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1120CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1121CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1121VCRASIISRKKEAKA1025
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1136CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1136VCRASIISRKKEAKA1025
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1141CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1148CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1155CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1155VCRASIISRKKEAKA1025
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1159CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1163CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1163VCRASIISRKKEAKA1025
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1165CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1165VCRASIISRKKEAKA1025
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1168CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1170CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1170VCRASIISRKKEAKA1025
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1176CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1176VCRASIISRKKEAKA1025
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1185CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1185VCRASIISRKKEAKA1025
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1186CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1186VCRASIISRKKEAKA1025
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1301CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1301VCRASIISRKKEAKA1025
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1302CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1304CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1308CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1315CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1315VCRASIISRKKEAKA1025
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1316CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1316VCRASIISRKKEAKA1025
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1317CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1317VCRASIISRKKEAKA1025
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1319CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1319VCRASIISRKKEAKA1025
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1320CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1320VCRASIISRKKEAKA1025
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1322CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1322VCRASIISRKKEAKA1025
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1323CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1324CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1324VCRASIISRKKEAKA1025
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1327CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1329CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1334CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1335CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1335VCRASIISRKKEAKA1025
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1339CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1351CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1351VCRASIISRKKEAKA1025
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1352CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1352VCRASIISRKKEAKA1025
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1353CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1353VCRASIISRKKEAKA1025
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1357CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1357VCRASIISRKKEAKA1025
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1359CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1359VCRASIISRKKEAKA1025
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1361CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1361VCRASIISRKKEAKA1025
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1364CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1364VCRASIISRKKEAKA1025
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1368CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1368VCRASIISRKKEAKA1025
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1369CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1369VCRASIISRKKEAKA1025
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1370CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1371CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1372CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1373CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1374CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1375CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1376CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1378CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1378VCRASIISRKKEAKA1025
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1379CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1379VCRASIISRKKEAKA1025
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1380CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1380VCRASIISRKKEAKA1025
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1383CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1383VCRASIISRKKEAKA1025
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1384CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1387CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1387VCRASIISRKKEAKA1025
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1391CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1391VCRASIISRKKEAKA1025
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1392CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1392VCRASIISRKKEAKA1025
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1393CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1397CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1398CRASIISRKKEAKAE1126
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1398VCRASIISRKKEAKA1025
ATP2A2-IFT81chr12110765822chr121106007241769DRB1-1399CRASIISRKKEAKAE1126

Top

Fusion breakpoint peptide structures of ATP2A2-IFT81

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
6340NQMSVCRASIISRKATP2A2IFT81chr12110765822chr121106007241769

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of ATP2A2-IFT81

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN6340NQMSVCRASIISRK-7.75776-7.86956
HLA-B14:023BVN6340NQMSVCRASIISRK-4.52646-5.56956
HLA-B52:013W396340NQMSVCRASIISRK-7.1873-7.2991
HLA-B52:013W396340NQMSVCRASIISRK-2.81174-3.85484
HLA-A11:014UQ26340NQMSVCRASIISRK-5.13576-5.24756
HLA-A24:025HGA6340NQMSVCRASIISRK-8.42076-8.53256
HLA-A24:025HGA6340NQMSVCRASIISRK-7.10496-8.14806
HLA-B27:056PYJ6340NQMSVCRASIISRK-9.28296-9.39476
HLA-B44:053DX86340NQMSVCRASIISRK-6.88262-6.99442
HLA-B44:053DX86340NQMSVCRASIISRK-5.46822-6.51132

Top

Vaccine Design for the FusionNeoAntigens of ATP2A2-IFT81

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
ATP2A2-IFT81chr12110765822chr121106007241020VCRASIISRKGTCTGCAGGGCATCTATCATTTCCCGTAAA
ATP2A2-IFT81chr12110765822chr121106007241120CRASIISRKTGCAGGGCATCTATCATTTCCCGTAAA
ATP2A2-IFT81chr12110765822chr121106007241221RASIISRKKAGGGCATCTATCATTTCCCGTAAAAAA
ATP2A2-IFT81chr12110765822chr12110600724920SVCRASIISRKTCAGTCTGCAGGGCATCTATCATTTCCCGTAAA

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
ATP2A2-IFT81chr12110765822chr121106007241025VCRASIISRKKEAKAGTCTGCAGGGCATCTATCATTTCCCGTAAAAAAGAAGCCAAAGCT
ATP2A2-IFT81chr12110765822chr121106007241126CRASIISRKKEAKAETGCAGGGCATCTATCATTTCCCGTAAAAAAGAAGCCAAAGCTGAG

Top

Information of the samples that have these potential fusion neoantigens of ATP2A2-IFT81

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
UCECATP2A2-IFT81chr12110765822ENST00000308664chr12110600724ENST00000242591TCGA-AX-A2H4-01A

Top

Potential target of CAR-T therapy development for ATP2A2-IFT81

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
HgeneATP2A2chr12:110720600chr12:110628724ENST00000308664+32149_6973998.0TransmembraneHelical%3B Name%3D1
HgeneATP2A2chr12:110720600chr12:110628724ENST00000395494+31949_69731016.0TransmembraneHelical%3B Name%3D1
HgeneATP2A2chr12:110720600chr12:110628724ENST00000539276+32049_69731043.0TransmembraneHelical%3B Name%3D1
HgeneATP2A2chr12:110720600chr12:110628725ENST00000308664+32149_6973998.0TransmembraneHelical%3B Name%3D1
HgeneATP2A2chr12:110720600chr12:110628725ENST00000395494+31949_69731016.0TransmembraneHelical%3B Name%3D1
HgeneATP2A2chr12:110720600chr12:110628725ENST00000539276+32049_69731043.0TransmembraneHelical%3B Name%3D1
HgeneATP2A2chr12:110765822chr12:110600724ENST00000308664-821254_273365998.0TransmembraneHelical%3B Name%3D3
HgeneATP2A2chr12:110765822chr12:110600724ENST00000308664-821296_313365998.0TransmembraneHelical%3B Name%3D4
HgeneATP2A2chr12:110765822chr12:110600724ENST00000308664-82149_69365998.0TransmembraneHelical%3B Name%3D1
HgeneATP2A2chr12:110765822chr12:110600724ENST00000308664-82190_110365998.0TransmembraneHelical%3B Name%3D2
HgeneATP2A2chr12:110765822chr12:110600724ENST00000395494-719254_2733381016.0TransmembraneHelical%3B Name%3D3
HgeneATP2A2chr12:110765822chr12:110600724ENST00000395494-719296_3133381016.0TransmembraneHelical%3B Name%3D4
HgeneATP2A2chr12:110765822chr12:110600724ENST00000395494-71949_693381016.0TransmembraneHelical%3B Name%3D1
HgeneATP2A2chr12:110765822chr12:110600724ENST00000395494-71990_1103381016.0TransmembraneHelical%3B Name%3D2
HgeneATP2A2chr12:110765822chr12:110600724ENST00000539276-820254_2733651043.0TransmembraneHelical%3B Name%3D3
HgeneATP2A2chr12:110765822chr12:110600724ENST00000539276-820296_3133651043.0TransmembraneHelical%3B Name%3D4
HgeneATP2A2chr12:110765822chr12:110600724ENST00000539276-82049_693651043.0TransmembraneHelical%3B Name%3D1
HgeneATP2A2chr12:110765822chr12:110600724ENST00000539276-82090_1103651043.0TransmembraneHelical%3B Name%3D2

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to ATP2A2-IFT81

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to ATP2A2-IFT81

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource